|
ISPOR 11th Annual
International Meeting
May 20-24, 2006
Marriott Philadelphia, Philadelphia, PA
|
|
TUESDAY, MAY 23,
2006 |
|
7:00AM-8:00AM |
STUDENT ROUNDTABLE DISCUSSIONS: BUILDING YOUR CAREER -
Room 402 |
|
|
Recent graduates from industry, consulting and academia will briefly
talk about their current jobs and what their day to day
responsibilities are. Ask them the questions about the current job
market and what a particular career path entails in this informal
and non-intimidating setting.
|
|
7:00AM-8:00AM |
POWERFUL DATA, MEANINGFUL ANSWERS: AN INTRODUCTION
TO THE HEALTHCARE COST & UTILIZATION PROJECT (HCUP) - Salon E
& F |
|
|
EDUCATIONAL SYMPOSIUM SPONSORED BY AHRQ-DHHS
HCUP is a unique and powerful data resource that captures
information on 90 percent of all hospital stays in the U.S. This
symposium will provide an overview to HCUP data and will introduce
participants to several HCUP software and tools, including HCUPnet -
the free, online query system that provides instant access to
aggregate statistics from HCUP data.
7:00AM – 7:20AM
AN INTRODUCTION TO HCUP DATA
Presenters will describe the HCUP initiative, discuss sources of
HCUP data, and highlight key features of the HCUP databases.
7:20AM – 7:45AM
EXAMPLES OF HCUP RESEARCH AND A DESCRIPTION OF FREE HCUP TOOLS
AND PRODUCTS THAT FACILITATE DATA ANALYSIS
Examples of research using HCUP databases will be discussed to
illustrate the diversity and breadth of research that these data
support. A demonstration of HCUPnet, an free, online query tool,
will be offered, as well as an overview of free HCUP tools and
software.
7:45AM -8:00AM
OBTAINING HCUP DATA AND USER SUPPORT
The roles of the HCUP Central Distributor, HCUP User Support, and
its Website are presented. Time will be allowed for audience
questions.
Symposium participants will receive a CD containing resources that
expand on topics covered in the session. CDs will include file
descriptions, information on how to access documentation, and
instructions on how to obtain HCUP data and tools.
Speakers: Thomas M. Brady, Ph.D., Research
Leader, Medstat, Washington, DC ; C. Allison Russo, M.P.H., Research Leader, Medstat,
Washington, DC
Host Organization:
Agency for Healthcare Research and Quality, United States Department
of Health and Human Services
|
|
|
8:00AM-9:00AM |
CONTRIBUTED PODIUM PRESENTATIONS - SESSION II |
|
|
Cost-Effective Analysis - Salon A
CE1
PHARMACOECONOMIC EVALUATION OF SINGLE DOSE AZITHROMYCIN EXTENDED
RELEASE (AZ-ER) FOR THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
(CAP)
Sorensen SV1, Baker TM1, Mallya UG2, Dirani RG3, Robets CS3
1Center for Health Economics and Policy, United BioSource
Corporation, Bethesda, MD, USA, 2The University of
Michigan, Ann Arbor, MI, USA, 3Pfizer Inc, New York, NY, USA
CE2
THE COST-EFFECTIVENESS OF ZEMPLAR IN THE NETHERLANDS
Nuijten MJ1, Siegert C2
1Ars Accessus Medica/Erasmus University Rotterdam , Amsterdam, The
Netherlands, 2St. Lucas Andreas Hospital, Amsterdam, The Netherlands
CE3
SHORT-TERM COST-EFFECTIVENESS OF RECOMBINANT ACTIVATED FACTOR VII IN
THE TREATMENT OF INTRACEREBRAL HEMORRHAGE
Earnshaw SR1, Wilson MR1, Joshi AV2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novo
Nordisk Inc, Princeton, NJ, USA
CE4
COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE
METAL STENTS (BMS) USING “REAL WORLD" DATA
Blackhouse G, Bowen J, Tarride JE, Hopkins R, O'Reilly D, Goeree RA
McMaster University, Hamilton, ON, Canada
Diabetes - Salon B
DB2
SELF REPORTED PREDICTORS OF DEPRESSIVE SYMPTOMATOLOGY IN AN ELDERLY
POPULATION WITH TYPE 2 DIABETES MELLITUS
Balkrishnan R1, Pawaskar MD1, Anderson RT2
1The Ohio State University College of Pharmacy, Columbus, OH, USA,
2Wake Forest University School of Medicine, Winston Salem, NC, USA
DB3
QUALITY OF LIFE IN PEOPLE WITH AND AT RISK FOR TYPE 2 DIABETES:
FINDINGS FROM THE STUDY TO HELP IMPROVE EARLY EVALUATION AND
MANAGEMENT OF RISK FACTORS LEADING TO DIABETES (SHIELD)
Chapman RH1, Grandy S2
1ValueMedics Research, Falls Church, VA, USA, 2AstraZeneca,
ilmington, DE, USA
DB4
STRESS AND COPING STRATEGIES ASSOCIATED WITH PHYSICAL AND MENTAL
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH TYPE 2
DIABETES MELLITUS.
Shah BM1, Borrego ME1, Gupchup GV2, Raisch DW3, Segal A1, Dodd MA1,
House N1, Apfeldorf W1, Feldner S1
1University of New Mexico, Albuquerque, NM, USA, 2Southern Illinois
University Edwardsville, Edwardsville, IL, USA, 3Department of
Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA
Formulary/Prescribing - Salon C
FP1
USE OF MEDICATION COVERAGE METHODOLOGY IN MEASUREMENT OF PATIENT
COMPLIANCE WITH PHARMACOTHERAPY
Stern L, Doyle J, Siegartel LR, Katz LM, Dolgitser M
Analytica International, New York, NY, USA
FP2
COST-EFFECTIVENESS OF A GLAUCOMA-SCREENING PROGRAM: A MODEL
EVALUATING THE RELATIVE CLINICAL AND ECONOMIC IMPACT IN COMMERCIAL
VS. SENIOR MEMBER POPULATIONS
Goldberg LD1, Walt JG2
1Goldberg, MD & Associates, Battle Ground, WA, USA, 2Allergan Inc,
Irvine, CA, USA
FP3
AN AUDIT OF 106 ECONOMIC ANALYSES CONTAINED IN AMCP DOSSIER
SUBMISSIONS 2002-2005
Colmenero F1, Brauer C1, Sullivan SD2, Watkins JB3, Neumann PJ4
1Harvard University, Boston, MA, USA, 2University of Washington,
Seattle, WA, USA, 3Premera BC, Mountlake Terrace, WA, USA, 4Tufts
University School of Medicine, Boston, MA, USA
FP4
NATIONAL ESTIMATES AND ASSOCIATED FACTORS OF ANTIPSYCHOTIC USE IN
AMBULATORY CARE FROM 1996 TO 2003
Sankaranarayanan J1, Puumala S2
1College of Pharmacy, University of Nebraska Medical Center, Omaha,
NE, USA, 2College of Medicine, University of Nebraska Medical
Center, Omaha, NE, USA
Patient-Reported Outcomes II - Salon D
PR5
VALIDATION OF THE HYPERPIGMENTATION TREATMENT SATISFACTION
QUESTIONNAIRE (HPTSQ)
Colman S1, Barrows S2, Nixon A3, Nixon M3, Taylor T2, Atkinson M4,
Miller T1
1Quintiles, San Francisco, CA, USA, 2Pfizer, Ann Arbor, MI, USA,
3Quintiles, Falls Church, VA, USA, 4Pfizer, San Diego, CA, USA
PR6
VALIDATION OF THE WORK PRODUCTIVITY QUESTIONNAIRE: RESULTS OF THE
MATRIX STUDY
Talati AR1, Pizzi LT1, Dahl N2, Gemmen E3
1Thomas Jefferson University, Philadelphia, PA, USA, 2Watson
Laboratories, Morristown, NJ, USA, 3Quintiles Strategic Research
Services, Falls Church, VA, USA
PR7
RISK INDICATORS FOR SELF-REPORTED JOINT PAIN AND MOTION LIMITATION
OUTCOMES IN HEMOPHILIA PATIENTS-THE HEMOPHILIA COST AND IMPACT OF
DISEASE STUDY-PART V
Wu J1, Globe D2, Riske B3, Wasserman J4, Johnson KA1
1University of Southern California, Los Angeles, CA, USA, 2Amgen,
Thousand Oaks, CA, USA, 3University of Colorado Health Sciences
Center, Aurora, CO, USA, 4University of Texas at Houston, Houston,
TX, USA
PR8
THE IMPACT OF ABNORMAL UTERINE BLEEDING ON HEALTH-RELATED QUALITY OF
LIFE: A META-ANALYSIS
Liu Z, Pinto L, Doan QV, Dubois R
Cerner Health Insights, Beverly Hills, CA, USA
|
|
9:15AM-10:15AM |
ISSUE PANEL - SESSION II (4 ISSUE PANELS) |
|
|
HEALTH POLICY
IP5: ORGANIZATION OF A TECHNOLOGY ASSESSMENT INSTITUTE FOR THE
UNITED STATES
Salon A
Moderator: Frank J Papatheofanis MD, MPH, PhD, Associate
Professor and Director, UCSD, San Diego, CA, USA
IP6: CONSEQUENCES OF DRUG COST CONTAINMENT: NEW EVIDENCE ON
CO-PAYMENTS, CO-INSURANCE, AND THERAPEUTIC SUBSTITUTION
Salon B
Moderator: Sebastian Schneeweiss MD, ScD, Associate Professor or
Medicine, Brigham and Women's Hospital, Harvard Medical School,
Boston, MA, USA
Panelists: Colin Dormuth ScD, MA, MS, Assistant Professor,
University of British Columbia, Vancouver, BC, Canada; Amanda
Patrick MS, Decision Scientist, Brigham and Women's Hospital,
Boston, MA, USA
PHARMACOECONOMIC / HEALTH ECONOMIC STUDY METHODOLOGY
IP7: ASSESSING HETEROGENEITY IN COST-EFFECTIVENESS ANALYSIS
Salon C
Moderator: Andrew Briggs DPhil, Professor, University of
Glasgow, Glasgow, United Kingdom
Panelists: Mark J Sculpher PhD, Professor, University of York,
York, United Kingdom; John R Cook PhD, Senior Director Health
Economic Statistics, Merck and Co, Blue Bell, PA, USA
RISK ASSESSMENT
IP8: HEALTH OUTCOMES APPROACHES TO RISK-BENEFIT ANALYSIS: HOW
READY ARE THEY?
Salon D
Moderator: Richard J Willke PhD, Senior Director/Group Leader,
Pfizer Inc, Bridgewater, NJ, USA
Panelists: Lou Garrison PhD, Professor, Pharmaceutical
Outcomes Research and Policy Program, University of Washington,
Seattle, WA, USA; F. Reed Johnson PhD, Senior Fellow and
Principal Economist, Research Triangle Institute, Research
Triangle Park, NC, USA; Larry Lynd PhD, Assistant Professor,
Faculty of Pharmaceutical Sciences, University of British
Columbia, Vancouver, BC, Canada
|
|
10:15AM-10:45AM |
BREAK, EXHIBITS, CONTRIBUTED POSTER PRESENTATIONS VIEWING -SESSION II
Franklin Hall, Level 4 |
|
|
Coffee sponsored by Quintiles:
|
 |
|
|
10:45AM-11:15AM |
ISPOR AWARDS PRESENTATION - Salon E & F |
|
|
2006 RESEARCH STARTER GRANTS IN HEALTH
OUTCOMES
This award offers $30,000 per year for up to two years.
Awardees:
Duska M. Franic PharmD, PhD, The University of Georgia,
College of Pharmacy, Athens, GA, USA
Winghan Jacqueline Kwong PharmD, PhD, The University of
Georgia, College of Pharmacy, College of Pharmacy, Athens, GA, USA
Amy L. Pakyz Pharmd, MS, Virginia Commonwealth University,
School of Pharmacy, Richmond, VA, USA
James W. Shaw PhD, PharmD, MPH, Thomas Jefferson University,
Jefferson Medical College, Philadelphia, PA, USA
ISPOR STUDENT CHAPTER PRESIDENTS SERVICE
AWARDS
Presented by: Zeba Khan PhD, RPh, ISPOR Student
Network Advisor & Executive Director, Pricing, General Medicines,
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
SERVICE AWARDS PRESENTATION
Presented by: Peter Neumann ScD, Center for the
Evaluation of Value and Risk in Health, Tufts University School of
Medicine, Boston, MA, USA
ISPOR SCIENTIFIC AWARDS
Moderator: C. Daniel Mullins PhD, Chair ISPOR Awards
Committee and Assistant Professor, University of Maryland, School of
Pharmacy, Baltimore, MD, USAISPOR
RESEARCH EXCELLENCE AWARD FOR METHODOLOGY EXCELLENCE
Announcement by: John Brooks PhD, Chair, ISPOR
Research Excellence Award for Methodology Excellence Task Force &
Associate Professor, University of Iowa, Iowa City, IA, USA
Awardee:
Maiwenn Al PhD, Senior Research Fellow,
Institute for Medical Technology Assessment, Erasmus MC – University
Medical Center, Rotterdam, Rotterdam, The Netherlands
The Analysis Of Incomplete Cost Data Due To
Dropout. Health Econ 2005;14:763-76.
Click here for biographical Info
ISPOR RESEARCH EXCELLENCE AWARD FOR
PRACTICE APPLICATION EXCELLENCE
Presented by: Ya-Chen Tina Shih, Chair, ISPOR Research
Excellence Award for Practical Application Excellence Task Force &
Associate Professor, M.D. Anderson Cancer Center, Houston, TX, USA.
Awardee:
Josephine Mauskopf PhD , Vice-President,
Health Economics, RTI Health Solutions, Research Triangle park, NC,
USA
“HIV Antiretroviral Treatment: Early Versus
Later.” J Acquir Immune Defic Syndr 2005;9:562-69.
Click here for biographical Info
BERNIE J. O’BRIEN NEW INVESTIGATOR AWARD
PRESENTATION
Presented by: Michael F. Drummond PhD, ISPOR Bernie J.
O’Brien New Investigator Award Task Force Chair & Professor of
Health Economics, Centre for Health Economics, University of York,
York, UK
Awardee:
John F.P. Bridges PhD, International Health
Economics and Outcomes Research Department of Tropical Hygiene and
Public Health, University of Heidelberg – Medical School,
Heidelberg, Germany
Click here for biographical Info
ISPOR 2006 AVEDIS DONEBEDIAN OUTCOMES
RESEARCH LIFETIME ACHIEVEMENT AWARD
Presented by: Joel Hay PhD, Chair, ISPOR Avedis
Donebedian Lifetime Achievement Award in Health Outcomes Task Force
& Associate Professor, University of Southern California, Los
Angeles, CA, USA
Awardee:
George Torrance MBA, PhD, Professor Emeritus,
Vice President, i3 Innovus, Toronto, ON, Canada
Click here for biographical Info
PhRMA FOUNDATION 2006 AWARD RECIPIENTS IN
HEALTH OUTCOMES
2006 Pre Doctoral Fellowship in Health Outcomes
This award offers $20,000 per year for up to two years. The
following individual was selected to receive this award:
Lisa M. Meckley,
University of Washington,
School of Pharmacy
2006 Post Doctoral Fellowship in Health Outcomes
This award offers $40,000 per year for up to two years. The
following individual has been selected receive the award:
Basit I. Chaudhry, Ph.D., University of California Los Angeles,
Division of General Internal Medicine
2006 Research Starter Grants in Health Outcomes
This award offers $30,000 per year for up to two years. The
following individuals have been selected receive the award:
Duska M. Franic, Pharm.D., Ph.D.,
The University of Georgia,
College of Pharmacy
Winghan Jacqueline Kwong, Pharm.D., Ph.D.,
The University of Georgia,
College of Pharmacy
Amy L. Pakyz, Pharm.D., M.S., Virginia Commonwealth University,
School of Pharmacy
James W. Shaw, Ph.D., Pharm.D., M.P.H.,
Thomas Jefferson University,
Jefferson Medical College
|
|
11:15AM-11:30AM |
INCOMING PRESIDENTIAL ADDRESS - Salon E & F |
|
|
Michael Drummond PhD, 2006-2007 ISPOR President & Professor
of Health Economics, University of York, Centre for Health
Economics, Heslington, York, UK
|
|
11:30AM-12:30PM |
SECOND PLENARY SESSION - Salon E & F |
|
|
COMPARATIVE EFFECTIVENESS & HEALTH CARE DECISION-MAKING
Moderator: Joseph DiCesare MPH, RPh, Head, Health
Economics & Outcomes Research, Novartis Pharmaceuticals Corporation,
East Hanover, NJ, USA
Speaker: Harvey V. Fineberg MD, PhD,
President & Chair, Institute of Medicine, Washington, DC, USA
This presentation will focus on outcomes research that pragmatically
supports health care decisions. Issues such as real-world,
decision-oriented research, integrating research into health care
decision-making effectively and efficiently, comparative
head-to-head studies, and the role of modeling studies (in lieu of
head-to-head studies) will be discussed.Speaker: Michael O'Grady PhD, former Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services & Senior Fellow, National Opinion Research Center at the University of Chicago, Washington D.C., USA
Dr O’Grady will focus on the economic aspects of comparative
effectiveness & health care decision-making. What are some of the
considerations a payer must take into account in thinking about
coverage and cost-sharing for new products? In an environment of
limited or no price sensitivity by providers, what are the
incentives for prudent use of new products? What are the
implications of new designs to increase more prudent purchasing
behavior by patients, for example, the increase popularity of Health
Savings Accounts (HSA)?
|
|
12:30PM-2:00PM |
LUNCH, EXHIBITS, CONTRIBUTED POSTER PRESENTATIONS VIEWING - SESSION II
GRAND OPENING - Franklin Hall, Level 4 |
|
|
Lunch Sponsored by GE Healthcare &
|
 |
| The Department of Health Policy of Thomas Jefferson
University |
 |
|
|
1:00PM-2:00PM |
HEALTH CARE POLICY DEVELOPMENT USING
OUTCOMES RESEARCH - Salon E & F |
|
|
EDUCATIONAL SYMPOSIUM SPONSORED BY DEPARTMENT OF HEALTH POLICY, JEFFERSON MEDICAL COLLEGE
1:00PM – 1:05PM
Welcome and Introductions
David B. Nash MD, MBA
The Dr. Raymond C. and Doris N. Grandon,
Professor and Chair
Department of Health Policy
Jefferson Medical College
1:05PM to 1:25PM
The EMR in Outcomes Research: The New Frontier
Diana Brixner, R.Ph., Ph.D., Associate Professor
Department Chair, Pharmacy Practice
Executive Director, Pharmacotherapy Outcomes
Research Center
College of Pharmacy University of Utah, Salt Lake City
1:25PM to 1:45PM
Using an EMR to Improve Quality of Care in a
National Network
James M. Gill, MD, MPH
Associate Professor of Family Medicine
Senior Scientist in Health Policy
Jefferson Medical College, Philadelphia, PA
1:45PM to 2:00PM
Q&A Discussion
Moderated by David B. Nash, MD, MBA
2:00PM
Closing Remarks
The ability to harness and
utilize the abundance of clinical information available is critical
to meeting regulatory standards, lowering costs, and improving
quality. This session will explore the use of outcomes research in
developing evidence-based healthcare policy. Presenters will assess
the value of data warehouses, using the Electronic Health Record as
an example, in conducting clinical research that promotes improved
health outcomes and pharmacovigilance. Industry leaders will provide
examples of how a data warehouse is utilized for quality improvement
and safety studies in a clinical setting. Following the
presentation, a panel of experts from the academic and industry
perspective will discuss current research studies goals in an
interactive format using real world examples. |
|
|
|
|
|
2:15PM-3:15PM |
CONTRIBUTED WORKSHOPS - SESSION III (8 WORKSHOPS, 6 CATEGORIES) |
|
|
Clinical Study Methodology
W17: ASSESSING THE CAUSAL EFFECTS OF TREATMENTS IN LONGITUDINAL
NATURALISTIC DATA
Salon A
DISCUSSION LEADERS: Miguel A Hernan MD, DrPH, Assistant
Professor of Epidemiology, Harvard School of Public Health,
Boston, MA, USA; Marshall Joffe MD, PhD, Assistant Professor of
Biostatistics, University of Pennsylvania, Philadelphia, PA,
USA; Douglas Faries PhD, Research Advisor, Eli Lilly and
Company, Indianapolis, IN, USA
Compliance/Adherence
W18: AN ECONOMIC FRAMEWORK TO UNDERSTAND MEDICATION COMPLIANCE
AND PERSISTENCE
Salon B
DISCUSSION LEADERS: Judith Shinogle PhD, Senior Economist, RTI,
International, Washington, DC, USA; Pamela Peele PhD, Associate
Professor and Vice Chair, University of Pittsburgh, Pittsburgh,
PA, USA; Rachel Elliot PhD, Clinical Senior Lecturer, The
University of Manchester, Manchester, United Kingdom
Cost Study Methodology
W19: CENSORED COST DATA ANALYSIS: RECENT DEVELOPMENTS AND
APPLICATION
Salon C
DISCUSSION LEADERS: Xin Ye PhD, Researcher, i3
Innovus, An
Ingenix Company, Eden Prairie, MN, USA; Henry Joe Henk PhD,
Researcher, i3 Innovus, An Ingenix Company, Eden Prairie, MN,
USA; Carolyn Harley PhD, Senior Director, i3 Innovus, An Ingenix
Company, Eden Prairie, MN, USA;
Lisa McGarry, M.P.H., Associate Director, i3 Innovus, Medford,
MA, USA
W20: COLLECTING AND USING PRODUCTIVITY DATA FROM CLINICAL TRIALS
Salon D
DISCUSSION LEADERS: Joshua J. Gagne PharmD, Outcomes Research
Fellow, Thomas Jefferson University, Philadelphia, PA, USA;
Kenneth D. Smith PhD, Project Director, Thomas Jefferson
University, Philadelphia, PA, USA; Laura T. Pizzi PharmD, MPH,
Associate Director of Research, Thomas Jefferson University,
Philadelphia, PA, USA
Formulary Development
W21: THE USE OF SOJA AND STEPS TO DETERMINE RATIONAL DRUG
CHOICES
Salon E & F
DISCUSSION LEADERS: Robert Janknegt PhD, Hospital
Pharmacist/Clinical Pharmacologist, Maasland Hospital, Sittard,
Sittard, Netherlands; Michael Scott BSc, PhD, Chief Pharmacist,
United Hospitals Trust, ANTRIM, United Kingdom
Health Care Policy Development
W22: PRESENTING UNCERTAINTY AROUND COST-EFFECTIVENESS ESTIMATES
TO DECISION MAKERS: HOW SURE ARE WE?
Liberty A
DISCUSSION LEADERS: Mohan Bala PhD, Director, Centocor Clinical
Research and Development, Inc, Malvern, PA, USA; Josephine Mauskopf PhD, Vice President, Health Economics, RTI Health
Solutions, Research Triangle Park, NC, USA; Gary Zarkin PhD,
Director, Behavioral Health Research Division, RTI
International, Research Triangle Park, NC, USA
W23: THE VALUE AND ACCEPTABILITY OF A BAYESIAN FRAMEWORK FOR
DRUG REIMBURSEMENT AND MARKET ACCESS DECISION-MAKING
Liberty C
DISCUSSION LEADERS: Jeroen P Jansen PhD, Project Manager, Mapi
Values, Houten, Netherlands; Keith Tolley MS, Director, Mapi
Values, Bollington, Cheshire, United Kingdom
Risk Assessment
W24: THE USE OF GENERAL PRACTICE RESEARCH DATABASES IN THE RISK
MANAGEMENT OF NEWLY LICENSED MEDICATIONS
Room 401
DISCUSSION LEADERS: Tjeerd P Van Staa MD, PhD, Head of Research,
General Practice Research Database, London, United Kingdom;
Susan Eaton MSPH, MT, Head of GPRD Customer Services USA,
General Practice Research database, Raleigh, NC, USA
|
|
3:15PM-3:30PM |
BREAK, EXHIBITS, CONTRIBUTED POSTER PRESENTATIONS VIEWING -SESSION
II
Franklin Hall, Level 4 |
|
|
Coffee sponsored by Quintiles:
|
|
|
|
3:30PM-4:30PM |
CONTRIBUTED WORKSHOPS - SESSION IV (8 WORKSHOPS) |
|
|
Clinical Study Methodology
W25: DEVELOPING ECONOMIC MODEL: PREDICTING CHANGE OVER TIME WITH
FRACTIONAL POLYNOMIALS
Salon A
DISCUSSION LEADERS: K Jack Ishak MSc, Statistician, Caro
Research Institute, Montreal, QC, Canada;
J. Jaime Caro MDCM,
FRCPC, FAC, President & Scientific Director, Caro Research
Institute, Concord, MA, USA
Compliance/Adherence
W26: CONTINUOUS ENROLLMENT AND THE INCOMPLETE INFORMATION
TRADEOFF
Salon B
DISCUSSION LEADERS: Chi-Chang Chen PhD, Post-Doctoral Fellow,
University of Maryland School of Pharmacy, Baltimore, MD, USA;
C. Daniel Mullins PhD, Professor and Chair, University of
Maryland School of Pharmacy, Baltimore, MD, USA; Fadia T Shaya
PhD, MPH, Assistant Professor, Associate Director, University of
Maryland, Baltimore, MD, USA
Cost Study Methodology
W27: INTRODUCTION TO DECISION-THEORETIC NETWORKS FOR
PHARMACOECONOMIC DECISION-MAKING
Salon C
DISCUSSION LEADERS: Gianluca Baio PhD, Research Fellow,
University College London, London, United Kingdom; Jeroen P
Jansen PhD, Project Manager, Mapi Values, Houten, Netherlands
W28: DETERMINING EVENT PROBABILITIES FOR COST-EFFECTIVENESS
ANALYSES FROM MODELING COUNT DATA
Salon D
DISCUSSION LEADERS: Quan V Doan, PharmD MSHS, Sr Associate
Director, Cerner Health Insights, Beverly Hills, CA, USA; Zhimei
Liu PhD, Sr Research Associate, Cerner Health Insights, Beverly
Hills, CA, USA
Health Care Policy Development
W29: VALUING HEALTH FOR REGULATORY CEA: RECOMMENDATIONS OF AN
IOM COMMITTEE
Salon E & F
DISCUSSION LEADERS: Dennis G Fryback PhD, Professor, University
of Wisconsin - Madison, Madison, WI, USA; Milton C. Weinstein
PhD, PhD, Principal Consultant, i3 Innovus; Professor,
Harvard School of Public Health and Harvard Medical School, Boston,
MA, USA
W30: UTILIZATION OF RETROSPECTIVE DATABASES TO INFORM EVIDENCE
BASED DRUG POLICY MAKING
Liberty A
DISCUSSION LEADERS: Christian A Gericke MD, MPH, MSc, Senior
Research Fellow in Health Care Management, Berlin University of
Technology, Berlin, Germany; Elaine Morrato MPH, Outcomes
Research Fellow, Johns Hopkins University, Baltimore, MD, USA;
Marya Zilberberg MD, FCCP, Regional Associate Director Outcomes
Research, Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ,
USA
W31:
POWERFUL DATA, MEANINGFUL ANSWERS: AN INTRODUCTION TO THE
HEALTHCARE COST & UTILIZATION PROJECT AND APPLICATIONS FOR CEA,
COI, AND HEALTH POLICY RESEARCH STUDIES
Liberty C
DISCUSSION LEADERS: Tom Brady PhD, Lead Health Services
Researcher, Medstat, Washington, D.C, USA; Allison Russo MPH,
Lead Health Services Researcher, Medstat, Washington, D.C, USA
QoL/PRO Methodology Issues
W32: VALIDATING COMPUTERIZED QUALITY OF LIFE MEASURES FOR USE IN
CLINICAL TRIALS
Room 401
DISCUSSION LEADERS: Chad J. Gwaltney PhD, Assistant Professor,
Brown University, Providence, RI, USA; Paul C. Beatty PhD,
Research Scientist, National Center for Health Statistics,
Hyattsville, MD, USA; Brian Tiplady PhD, Senior Clinical
Scientist, Invivodata, Inc, Edinburgh, United Kingdom
|
|
4:45PM-5:45PM |
ISPOR FORUMS |
|
|
|
|
4:45PM – 5:45PM |
ISPOR COMMENTS ON FDA PATIENT REPORTED
OUTCOMES GUIDANCE - Salon A |
|
|
ISPOR PRO SIG PRO/QOL Information in Regulatory & Health Care
Decisions Working Group Chair: Patrick Marquis, MD, MBA, Mapi
Values, Boston, MA, USA and Cross-Cultural & Translational
Adaptation (Cta) Working Group Chair: Diane Wild, MSc, BSc,
Oxford Outcomes, Oxford, UK
The ISPOR PRO SIG PRO/QOL Information in Regulatory & Health Care
Decisions working group developed the response to the
Patient-reported Outcomes Draft FDA Guidance. The response was based
on comments and suggestions received from over 50 ISPOR members.
This Forum will discuss PRO results and issues (pros and cons).
reported Outcomes Draft FDA Guidance. The response was based on
comments and suggestions received from over 50 ISPOR members. This
Forum will discuss PRO results and issues (pros and cons).
|
|
4:45PM – 5:45PM |
TRANSLATING RESEARCH TO PRACTICE SIG FORUM
- Salon B |
|
|
Translating Research to Practice SIG, Chair: Peter Wong PhD, MBA,
RPh, Mercy Health Partners, Southwest Region, Cincinnati, OH,
USA
This Forum will discuss how healthcare professionals, representing
employers, insurers, health plans, drug and health care services
management, can translate pharmacoeconomics and outcomes research
into practice for cost-effective, optimal patient/employee outcome.
|
|
4:45PM – 5:45PM |
PATIENT REGISTRY GLOBAL STRATEGIC
APPLICATIONS - Salon C |
|
|
Working Group Co-Chairs: Leanne Larson MHA, Sr. Vice
President, Patient Registries, Ovation Research Group, Highland
Park, IL, USA; Melva Covington MPH, MBA, PhD, Team Leader,
Global Health Outcomes, Eli Lilly, Indianapolis, IN, USA; Jeffrey
Trotter MM, President, Ovation Research Group, Highland Park,
IL, USA The Strategic Applications for Patient Registries SIG has
focused on consolidating our scope of activities by 1) integrating
the US and Global SIGS into one group because of similar interests
expressed by teams and 2) preparing a White Paper to inform how best
to develop and operationalize the use of patient registries. The
team has successfully integrated the functions and have had several
meetings to discuss key issues regarding how registries are utilized
in health outcomes and in the Pharmaceutical industry. We have
approved the core outline for a White Paper, which can serve as a
policy guidance document for ISPOR.
Relative to the future, a new registry assessment initiative has
been launched by AHRQ to provide similar guidance as a part of the
evaluation infrastructure developed to support MMA Part D. The focus
of our SIG during the next year will be to evaluate how our
operation complements or overlaps with this larger effort and
provide strategic recommendations to ISPOR leadership.
|
|
4:45PM – 5:45PM |
RETROSPECTIVE DATABASES - VALUABLE
RESOURCES IF EFFICIENTLY UTILIZED - Salon D |
|
|
Retrospective Database SIG, Chairs: Michael Johnson, PhD,
Associate Professor, University of Houston, College of Pharmacy and
William D. Marder PhD, Medstat, Cambridge, MA, USA Now in our second year, progress on each of the Working Groups will
be presented in an open forum (everyone welcome!) Opportunity for
discussions after the presentations. |
|
|
|
|
4:45PM – 5:45PM |
ISPOR MEDICAL DEVICE & DIAGNOSTICS OUTCOMES
RESEARCH: ISSUES & GOOD RESEARCH PRACTICES - Salon E&F |
|
|
ISPOR has launched an initiative to address methodological
issues and good research practices when conducting outcomes
research for medical devices and diagnostics. The product of
this initiative is a book titled: Medical Device & Diagnostics
Outcomes Research: Issues & Good Research Practices (THE BOOK).
THE BOOK will address issues related to current health
technology assessment methodologies and recommend good outcomes
research practices that are specifically "tailored" for
fast-paced, medical device and diagnostics technology
environment. This initiative is a joint project of the ISPOR US
Medical Device & Diagnostics Council and the ISPOR European
Medical Device & Diagnostics Council.
|
| US Medical Device & Diagnostics Council
|
| Moderator: Stephen Hull, AdvaMed, Washington, DC, USA |
Speaker: Stacey Ackerman MSE, PhD, Vice
President, Covance Health Economics & Outcomes Services, San
Diego, CA, USA (invited)
|
| Research Differentiation Section Working Group |
| Speaker: TBD |
| |
| Evidence Hierarchy Section Working Group |
Speaker: Michael Chernew PhD University of Michigan, Health
Mgmt & Policy, Ann Arbor, MI, USA (invited)
|
| Clinical Outcomes Section Working Group |
Speaker: David Polly MD, Professor and Chief
of Spine Surgery, Department of Orthopedic Surgery, University
of Minnesota, Minneapolis, MN, USA (invited)
|
| Economic Outcomes Working Group |
Speaker: Seema Sonnad, PhD, Associate Professor, Dept of
Surgery, University of Pennsylvania, Philadelphia, PA USA
|
| Patient Reported Outcomes Working Group |
| Speaker: Susan Mathias, MPH, Vice President, Ovation
Research Group, San Francisco, CA, USA |
| |
|
|
4:45PM – 5:45PM |
ISPOR VISION 2010 IMPLEMENTATION TASK FORCE
FINAL REPORT - Liberty A |
|
|
Vision 2010 Implementation Task Force, Co-Chairs: Lieven Annemans
MSc, PhD, Ghent University and
HEDM and IMS Health, Brussels, Belgium and Isao Kamae MD,
School of Medicine, Kobe University,
Kobe, Japan |
|
|
|
|
5:45PM-7:30PM |
EXHIBITORS' WINE & CHEESE RECEPTION & CONTRIBUTED POSTER
PRESENTATIONS VIEWING - SESSION II - Franklin Hall, Level 4 |
|
|
|
|
7:30PM |
VALUE IN HEALTH EDITORIAL ADVISORY BOARD DINNER MEETING (BY
INVITATION ONLY) Independence Ballroom I & II |
11th Annual Meeting Main Page
|
|
